A study published in Nature on 9 October 2026 has characterized how porcine circovirus type 3 (PCV3) behaves in conventionally weaned pigs, finding that the virus establishes an infection without causing fever or reducing weight gain. Researchers infected seven-week-old pigs that tested negative for PCV3 and tracked them for 35 days, comparing them against a mock-infected control group.
According to Nature, the work was carried out by researchers affiliated with the Key Laboratory of Bacteriology at the Ministry of Agriculture and the College of Veterinary Medicine at Nanjing Agricultural University in Nanjing, China. The study was supported by the National Key Research and Development Program of China.
Why it matters
PCV3 has been detected in swine with growing frequency, but how harmful it actually is to ordinary weaned pigs has remained poorly understood. The new findings describe a virus that spreads through the body and settles in immune tissues while leaving the animals outwardly healthy — a profile that complicates diagnosis and on-farm surveillance.
The authors state that the results will support the development of a commercial vaccine against PCV3. Because the infected pigs showed no measurable signs of illness, any vaccine or control strategy will likely need to rely on laboratory testing rather than observation of sick animals.
No fever, no drop in growth
The researchers randomly assigned the pigs to either a mock group or an infection group and monitored rectal temperature across the full 35-day observation period. Nature reports that no meaningful difference in temperature appeared between the two groups at any point, with the statistical result exceeding the 0.05 threshold.
Body weight rose in both groups over the course of the experiment. The difference in relative average daily gain between infected and control pigs was also not statistically significant, according to the study.
Spleen and inguinal lymph node indices — measures of organ size relative to body weight — likewise showed no difference between the groups.
Taken together, the clinical picture is one of an infection that does not produce the fever and wasting that might prompt a farmer or veterinarian to single out an animal for testing.
Viral load peaks early and persists
Using qPCR, the team measured PCV3 DNA in serum. The highest concentration appeared at 1 day post-infection, at roughly 10^7.7 copies per milliliter. That level fell to about 10^6.0 copies per milliliter by day 35, but the virus remained detectable in blood for the entire experiment.
At the end of the 35-day period, the pulmonary hilar lymph nodes held the heaviest viral burden, at 10^9.2 copies per gram of tissue. Lungs and spleens carried the next highest amounts, while the remaining lymphoid tissues and solid organs fell within a range of 10^6.5 to 10^8.5 copies per gram.
The distribution pattern led the authors to describe PCV3 as lymphotropic — that is, tending to concentrate in lymphatic tissue.
Tissue damage and where the virus was found
Histopathology, the microscopic examination of tissue, revealed interstitial pneumonia marked by thickened alveolar septa and shedding of the bronchial mucosa. The researchers also observed localized disruption of muscle fibers accompanied by mild necrosis of heart muscle cells, along with mild vacuolar changes in liver cells.
Immunohistochemistry, a technique that labels specific proteins in tissue, detected PCV3 antigen as brown granular deposits in the cytoplasm of lymphocytes and macrophage-like cells within lymph nodes and the spleen.
The study's conclusions rest on a controlled experimental design: all animals began free of PCV3, and the comparison group received a mock preparation rather than the virus. That setup allows the observed tissue changes and viral measurements to be attributed to the infection rather than to unrelated farm conditions, though the authors note that the pathogenic profile of PCV3 in conventional weaned pigs had previously been incompletely defined.
The article is published under a Creative Commons Attribution 4.0 International License, and the full citation lists Zhang, B., Cai, Y., Xiang, W. and colleagues in Scientific Reports.
What to watch next is whether these findings translate into a candidate vaccine, since the study's stated aim is to provide a foundation for commercial PCV3 vaccine development.
